OncoGenex Pharmaceuticals Inc. Fund Company Profile
Information
19820 North Creek Parkway
Bothell WA 98021
425-686-1500
Description
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The companys product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.